Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

Published:2021-01 Issue:1 Volume:84 Page:130-138
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Loft Nikolai,Halling Anne-Sofie,Egeberg Alexander,Skov Lone

Funder

Pfizer

Eli Lilly

Novartis

AbbVie

Janssen Pharmaceuticals

National Psoriasis Foundation

Simon Spies Foundation

Kgl Hofbundtmager Aage Bang Foundation

Sanofi

Janssen-Cilag

LEO Pharma

Publisher

Elsevier BV

Subject

Dermatology

Reference56 articles.

1. The IL-23/Th17 axis in the immunopathogenesis of psoriasis;Di Cesare;J Invest Dermatol,2009

2. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial;Krueger;J Allergy Clin Immunol,2015

3. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial;Papp;Br J Dermatol,2015

4. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis;Sofen;J Allergy Clin Immunol,2014

5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study;Papp;Br J Dermatol,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologic treatment sequences in moderate‐to‐severe psoriasis;Australasian Journal of Dermatology;2024-07-22

2. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?;American Journal of Clinical Dermatology;2024-07-13

3. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry;Drugs - Real World Outcomes;2024-06-24

4. Multi‐treatment resistance to biological treatment in patients with psoriasis: Definitions and implications;Journal of the European Academy of Dermatology and Venereology;2024-05-31

5. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort;International Journal of Dermatology;2024-01-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3